EverSource Wealth Advisors LLC Acquires 405 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

EverSource Wealth Advisors LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,125.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 441 shares of the company’s stock after purchasing an additional 405 shares during the period. EverSource Wealth Advisors LLC’s holdings in Medpace were worth $147,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Pallas Capital Advisors LLC lifted its position in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after buying an additional 2,101 shares in the last quarter. Barclays PLC increased its position in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Medpace during the third quarter valued at approximately $3,098,000. Finally, Loomis Sayles & Co. L P grew its stake in Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after purchasing an additional 13,880 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $381.44.

Medpace Trading Up 0.4 %

Shares of NASDAQ MEDP opened at $326.34 on Tuesday. The company has a market capitalization of $9.94 billion, a P/E ratio of 25.84, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a 50 day moving average of $339.97 and a 200-day moving average of $340.56.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.